Literature DB >> 21342433

Bleeding tendency and impaired platelet function in a patient carrying a heterozygous mutation in the thromboxane A2 receptor.

T Kamae1, K Kiyomizu, T Nakazawa, S Tadokoro, H Kashiwagi, S Honda, Y Kanakura, Y Tomiyama.   

Abstract

BACKGROUND: Thromboxane A(2) receptor (TXA(2)R) abnormality appears to dominantly disturb platelet function.
OBJECTIVES: To reveal a molecular genetic defect in a patient with TXA(2)R abnormality and investigate the mechanism for the impaired response to TXA(2). PATIENT: The proband (OSP-2, PT) was a 7-year-old Japanese girl, suffering from repeated mucocutaneous bleeding. METHODS AND
RESULTS: U46619 (2.5 and 10 μm)-induced platelet aggregation was remarkably impaired in the proband and her father. Immunoblots showed that TXA(2)R expression levels in their platelets were approximately 50% of controls, and nucleotide sequence analysis revealed that they were heterozygous for a novel mutation, c.167dupG in the TXA(2)R cDNA. Expression studies using Chinese hamster ovary (CHO) cells indicated that the mutation is responsible for the expression defect in TXA(2)R. We then examined α(IIb)β(3) activation by employing an initial velocity analysis and revealed that U46619 failed to induce a sustained α(IIb)β(3) and Rap1B activation in the proband. In addition, platelet secretion as monitored by P-selectin expression was markedly impaired in response to U46619 but not to ADP. The interaction between secreted ADP and P2Y(12) has been shown to play a critical role in the sustained α(IIb)β(3) activation (Kamae et al. J Thromb Haemost 2006; 4: 1379). As expected, small amounts of exogenous ADP (0.5 μm) partially restored the sustained α(IIb)β(3) activation induced by U46619.
CONCLUSION: Our present data strongly suggest that the impaired platelet activation in response to U46619 in the heterozygous subject for the TXA(2)R mutation is, at least in part, as a result of the decrease in ADP secretion.
© 2011 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21342433     DOI: 10.1111/j.1538-7836.2011.04245.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  6 in total

1.  The vesicular glutamate transporter VGLUT3 contributes to protection against neonatal hypoxic stress.

Authors:  Stéphanie Miot; Nicolas Voituron; Adélaïde Sterlin; Erika Vigneault; Lydie Morel; Boris Matrot; Nelina Ramanantsoa; Bénédicte Amilhon; Odile Poirel; Eve Lepicard; Salah El Mestikawy; Gérard Hilaire; Jorge Gallego
Journal:  J Physiol       Date:  2012-08-13       Impact factor: 5.182

2.  Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel.

Authors:  Ban B Dawood; Gillian C Lowe; Marie Lordkipanidzé; Danai Bem; Martina E Daly; Mike Makris; Andrew Mumford; Jonathan T Wilde; Steve P Watson
Journal:  Blood       Date:  2012-09-21       Impact factor: 22.113

Review 3.  Rare platelet GPCR variants: what can we learn?

Authors:  S P Nisar; M L Jones; M R Cunningham; A D Mumford; S J Mundell
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

Review 4.  Inherited platelet disorders: toward DNA-based diagnosis.

Authors:  Claire Lentaigne; Kathleen Freson; Michael A Laffan; Ernest Turro; Willem H Ouwehand
Journal:  Blood       Date:  2016-04-19       Impact factor: 25.476

5.  Identification and Characterization of Novel Variations in Platelet G-Protein Coupled Receptor (GPCR) Genes in Patients Historically Diagnosed with Type 1 von Willebrand Disease.

Authors:  Jacqueline Stockley; Shaista P Nisar; Vincenzo C Leo; Essa Sabi; Margaret R Cunningham; Jeroen C Eikenboom; Stefan Lethagen; Reinhard Schneppenheim; Anne C Goodeve; Steve P Watson; Stuart J Mundell; Martina E Daly
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

6.  TBXA2R gene variants associated with bleeding.

Authors:  Stuart James Mundell; Andrew Mumford
Journal:  Platelets       Date:  2018-08-08       Impact factor: 3.862

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.